EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

November 2026 Letter to the Editor

Mahsa Zarghami, Janine Overcash, Karen DiValerio Gibbs

Oncology Nursing Forum · 09.11.2026 · 53 (6)

DOI: 10.1188/26.onf.e26535394 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Oncology Nursing Forum, online erschienen am 09.11.2026. Verfasst von Mahsa Zarghami und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mahsa Zarghami. Hauptthemen laut MEDLINE: Oncology Nursing, Antineoplastic Agents. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

POLICY FOR LETTERS TO THE EDITOR: Selection of letters to be published is the decision of the editor. For acceptance, letters must be signed. A letter can appear anonymously if requested by the author. All letters are subject to editing. A letter that questions, criticizes, or responds to a previously published Oncology Nursing Forum article automatically will be sent to the author of that article for a reply. This type of collegial exchange is encouraged. Send letters to ONFEditor@ons.org.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncology NursingAntineoplastic AgentsHumans

Stichwörter der Autor:innen

adverse eventantineoplasticchemotherapyextravasationside effect management

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Mahsa Zarghami.
  • Janine Overcash.
  • Karen DiValerio Gibbs.

Zitieren

APA

Zarghami, M., Overcash, J., & DiValerio Gibbs, K. (2026). November 2026 Letter to the Editor. Oncology Nursing Forum, 53(6). https://doi.org/10.1188/26.onf.e26535394

Vancouver

Zarghami M, Overcash J, DiValerio Gibbs K. November 2026 Letter to the Editor. Oncology Nursing Forum. 2026;53(6). doi:10.1188/26.onf.e26535394

BibTeX
@article{Zarghami2026,
  author = {Zarghami, Mahsa and Overcash, Janine and DiValerio Gibbs, Karen},
  title = {November 2026 Letter to the Editor},
  journal = {Oncology Nursing Forum},
  year = {2026},
  volume = {53},
  number = {6},
  doi = {10.1188/26.onf.e26535394}
}
Kostenlos starten →